Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

NCT06639854 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT06639854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06639854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
Lead sponsor
M.D. Anderson Cancer Center
Phase
Not applicable
Overall status
Recruiting
Start date
November 20, 2024
Completion date
December 31, 2027
Enrollment
105 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus cell mediated immunity, hematopoietic cell transplant